PIK3CA and cancer: The identification of oncogenic mutations that result in activation of the well-known PI3K/AKT/mTOR and RAS/MAPK pathways has enabled exploration of drug-based therapeutic interventions using small-molecule inhibitors that were developed for cancer treatment (Figure 2).